Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056797 · ClinicalTrials.gov registry record · Phase 2
Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT00056797 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 92 participants.
The verdict
NCT00056797, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
This study will evaluate whether the HIV vaccine ALVAC vCP1452 given in combination with interleukin-2 (IL-2), also known as aldesleukin, can increase immune system function in people with HIV infection.
Interventions
- DRUG Interleukin-2
- BIOLOGICAL ALVAC HIV vaccine (vCP1452)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2002-03 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00056797
The ClinicalTrials.gov registry entry for NCT00056797 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Interleukin-2 is the first listed.
NCT00056797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00056797 about?
NCT00056797 is a clinical study titled "Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV". This study will evaluate whether the HIV vaccine ALVAC vCP1452 given in combination with interleukin-2 (IL-2), also known as aldesleukin, can increase immune system function in people with HIV infection.
What is the current status of trial NCT00056797?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2002-03. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00056797?
The interventions under investigation include: Interleukin-2 (DRUG), ALVAC HIV vaccine (vCP1452) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00056797?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.